Drug Profile
ASC JM.X2
Alternative Names: ASC-JM.X2; ASC-JMX2Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator AndroScience Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor degradation enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Benign prostatic hyperplasia; Prostate cancer
Most Recent Events
- 05 Sep 2023 Preclinical development is ongoing in Benign-prostatic-hyperplasia in USA (AndroScience Corporation pipeline, August 2023)
- 05 Sep 2023 Preclinical development is ongoing in Prostate-cancer in USA (AndroScience Corporation pipeline, August 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Benign-prostatic-hyperplasia in USA